Galectin reports Q3 2022 net loss $8.6M; NAVIGATE trial 88% enrolled

GALECTIN THERAPEUTICS INC

2022-Q3 EPS reported -$0.47

Net loss $8.6M ($0.14/sh) for Q3 2022, unchanged from Q3 2021.
Cash $15.8M; plus $60M credit line; expects funding through Dec 2024.
NAVIGATE trial: 279 of 315 patients randomized, 74 in screening; target full enrollment around end-2022.
FDA allowed IND for belapectin + Keytruda in head and neck cancers.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GALECTIN THERAPEUTICS INC reported the three months ended September 30, 2022 results: net income $8.6 million, EPS ($0.14) per share.

Period: the three months ended September 30, 2022
Net income: $8.6 million
EPS: ($0.14) per share
Result: reported results

Exact text from the filing

For the three months ended September 30, 2022, the Company reported a net loss applicable to common stockholders of $8.6 million, or ($0.14) per share

View on SEC.gov

Browse all earnings releases →

GALECTIN THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001140361-22-041172

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.